Back to company

REFLAB ApS: Financial statements 2018

CVR: 15322586

REFLAB ApS (CVR 15322586) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 3,308,574 and a net result of DKK -426,275 compared with DKK -1,008,355 the year before. That is an increase of 18.9% compared with the year before. Equity amounted to DKK 242,481. The solvency ratio was 5.9%. The company had 8 employees in the financial year.

Gross Profit
3,308,574 kr.
Profit/Loss
-426,275 kr.
Equity
242,481 kr.
Total Assets
4,127,481 kr.
Employees
8

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2018-3.3 mio.-426 t.242 t.8
2017-2.8 mio.-1 mio.669 t.7
2016-1.7 mio.-1.8 mio.1.7 mio.6
2015-3 mio.-382 t.3.5 mio.-
2014-4.6 mio.1.1 mio.3.9 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on REFLAB ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2018

REFLAB ApS: The 2017 annual report is outFeb 19, 2018

REFLAB ApS has published its annual report for 2017. Gross profit came to DKK 2,782,613, and the net result was DKK -1,008,355.

About REFLAB ApS

REFLAB ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 1991. The company is registered under the industry Traditionelle, komplementære og alternative behandlingsformer. The company was previously named REFERENCELABORATORIET ApS. The management consists of Gert Pynt Andersen. The company is owned by R-Biopharm AG. The company has 7 employees. In 2025, the company reported a gross profit of DKK 4,582,184 and a net result of DKK -1,792,430 compared with DKK 652,577 the year before. Equity amounted to DKK -635,048.